呼吸器疾患検査市場-検査タイプ別、用途別、エンドユーザー別、地域別、競合、世界の産業規模、シェア、動向、機会、予測、2018～2028年

世界の呼吸器疾患検査市場は、2022年に60億1,000万米ドルの評価額を達成し、予測期間を通じて堅調な拡大が見込まれており、予想年間平均成長率（CAGR）は5.72%で、2028年には83億米ドルに達する見込みです。

この市場には、呼吸器診断と総称される肺機能と関連プロセスの評価が含まれます。これには、喘息、慢性閉塞性肺疾患（COPD）、肺がん、気管支炎、肺線維症などの状態を検出することを目的とした、機械的、画像的、分子的診断検査が含まれます。この領域で適用される技術には、スパイロメトリー、オキシメトリー、経皮的CO2モニタリング、鼻腔吸気圧（SNIP）、胸部X線検査、コンピュータ断層撮影（CT）スキャンなどがあります。特定のケースでは、睡眠時無呼吸症候群や夜間低換気の診断のために睡眠検査が実施されることもあります。

主な市場促進要因：

呼吸器疾患の負担増：呼吸器疾患の有病率の増加は市場成長の極めて重要な促進要因です。喫煙の増加、飲酒、座りがちなライフスタイル、ストレスなどの要因が、COPD症例や肺がんのような他の重篤な呼吸器疾患の拡大に寄与しています。さらに、COPD診断や外来患者管理のためのモノのインターネット（IoT）や人工知能（AI）を含む呼吸器診断検査技術の進歩が、市場拡大にプラスの影響を与えています。民間病院や医療センターでは、呼吸器診断装置の需要が高まっています。政府や非政府組織（NGO）も質の高い医療へのアクセス強化に努めており、市場の成長を促進しています。呼吸器症状は、プライマリ医療センターで診察を受ける主な理由の1つであり、呼吸器疾患の負担増と呼吸器疾患検査需要への影響を強調しています。

検査機器とモダリティの技術的進歩：同市場は技術的進歩によって大きな牽引力となっています。この分野の主な参入企業は、治療プロトコルを最適化し、患者の転帰を向上させるために、人工知能（AI）と機械学習技術の開発に注力しています。例えば、Respira Labs社は、肺機能をモニタリングするSylveeというAIを搭載したウェアラブルデバイスを発表し、COPDの早期診断と管理を可能にしました。CAIRE Inc.がMGC Diagnostics Holdingsを買収して提供製品を多様化し、市場での地位を固めたように、買収も市場成長に寄与しています。

高齢者人口の増加：世界の高齢者人口は急増すると予測され、それに伴い呼吸器系の生理的変化により呼吸器感染症にかかりやすくなります。高齢者では呼吸器疾患がより重篤になるため、これらの疾患の早期発見と理解は患者の予後を改善する上で極めて重要です。このため、高齢者人口の増加が呼吸器疾患検査市場の成長を促進しています。

主な市場課題

高コストと熟練専門家の不足：診断手順には多額の費用がかかる上、技術の急速な進歩により有資格の専門医が不足しています。この不足は、器具の取り扱いや検査の実施など、手順の適切な実施を妨げ、市場の成長を阻害しています。

限られた償還政策：世界的に償還政策が不十分または存在しないため、診断検査の需要が阻害され、市場成長が制限される可能性があります。適切な償還制度がなければ、患者は呼吸器疾患検査を受けることをためらい、特にアジア太平洋では診断と治療の遅れにつながる可能性があります。

主な市場動向：

ポイントオブケア検査（POCT）の拡大：呼吸器疾患のポイントオブケア検査の拡大により、さまざまな医療環境での迅速で便利な検査が容易になっています。POCT機器は迅速な結果を提供し、特に資源が限られた環境ではタイムリーな診断とモニタリングを支援します。

人工知能（AI）の統合：AI主導のアルゴリズムは、呼吸器疾患検査結果の精度と解釈を高め、より正確な診断と個人に合わせた治療法の推奨につながります。AIは、人間の専門家が見逃す可能性のあるパターンや相関関係を特定することができ、呼吸器疾患の診断に革命をもたらします。

セグメント別洞察

検査タイプ別洞察：市場は画像検査、機械検査、体外診断検査に分類されます。体外診断用検査は、その広範な採用と有効性により圧倒的なシェアを占めています。画像検査は、精密な診断方法に対する需要の高まりと画像技術の進歩により急成長を遂げています。

エンドユーザー別洞察：総合的ケアと集学的アプローチにより、病院が市場を独占しています。診断センターは、外来患者の増加傾向や単独診断サービスの需要に後押しされて急成長しています。

地域別洞察：北米は、高度な医療インフラ、医療費、呼吸器疾患の流行により優位性を維持しています。アジア太平洋は、人口の多さ、都市化、呼吸器疾患に対する意識の高まり、医療インフラの改善などを背景に急成長しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 呼吸器疾患検査の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 検査タイプ別（画像検査、機械検査、体外診断検査）
  • 用途別（COPD、肺がん、喘息、結核）
  • エンドユーザー別（病院、診断センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 北米の呼吸器疾患検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 検査タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の呼吸器疾患検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 検査タイプ別
  • 用途別
  • エンドユーザー別
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の呼吸器疾患検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 検査タイプ別
  • 用途別
  • エンドユーザー別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の呼吸器疾患検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 検査タイプ別
  • 用途別
  • エンドユーザー別
• 南米：：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの呼吸器疾患検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 検査タイプ別
  • 用途別
  • エンドユーザー別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

第12章 市場動向と発展

第13章 呼吸器疾患検査の世界市場のSWOT分析

第14章 競合情勢

• Beckton Dickinson and Company
• Koninklijke Philips N.V.
• ResMed Inc.
• Medtronic PLC
• Carestream Health
• MG Diagnostic Corporation
• Abbott Laboratories
• ThermoFisher Scientific
• Biomerieux
• QIAGEN

第15章 戦略的提言

第16章 調査会社・免責事項

The Global Respiratory Disease Testing Market achieved a valuation of USD 6.01 Billion in 2022 and is poised for robust expansion throughout the forecast period with a projected Compound Annual Growth Rate (CAGR) of 5.72% and expected to reach USD 8.30 Billion through 2028. This market encompasses the evaluation of lung function and associated processes, collectively known as respiratory diagnostics. This involves a spectrum of mechanical, imaging, and molecular diagnostic tests aimed at detecting conditions such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, bronchitis, and pulmonary fibrosis. The techniques applied in this domain include spirometry, oximetry, transcutaneous CO2 monitoring, sniff nasal inspiratory pressure (SNIP), chest X-ray, and computed tomography (CT) scan. In specific cases, sleep studies may also be conducted to diagnose sleep apnea and nocturnal hypoventilation.

Key Market Drivers:

Growing Burden of Respiratory Diseases: The rising prevalence of respiratory diseases acts as a pivotal driver for market growth. Factors such as increased smoking, alcohol consumption, sedentary lifestyles, and stress have contributed to the escalation of COPD cases and other severe respiratory conditions like lung cancer. Moreover, advancements in respiratory diagnostic testing technologies, including Internet of Things (IoT) and Artificial Intelligence (AI) for COPD diagnosis and outpatient management, have positively influenced market expansion. Private hospitals and healthcare centers exhibit escalating demand for respiratory diagnostic devices. Government and non-governmental organizations (NGOs) are also striving to enhance access to quality healthcare, fostering market growth. Respiratory symptoms are among the primary reasons for seeking medical consultation in primary healthcare centers, underscoring the growing burden of respiratory diseases and their impact on the demand for respiratory disease testing.

Technological Advancements in Testing Devices and Modalities: The market is witnessing significant traction from technological advancements. Key players in this arena are focusing on the development of Artificial Intelligence (AI) and machine learning technologies to optimize treatment protocols and enhance patient outcomes. For example, Respira Labs introduced an AI-powered wearable device named Sylvee for monitoring lung function, enabling early COPD diagnosis and management. Acquisitions are also contributing to market growth, as seen through CAIRE Inc.'s acquisition of MGC Diagnostics Holdings to diversify their offerings and consolidate their position in the market.

Increasing Geriatric Population: The global geriatric population is projected to surge, and with it, the susceptibility to respiratory infections due to physiological changes in the respiratory system. As respiratory diseases are more severe in the elderly, early detection and understanding of these conditions are crucial for improving patient outcomes. The rising elderly population thus fuels the growth of the respiratory disease testing market.

Increasing Government Initiatives: Government initiatives are pivotal in fostering advancements and growth in the respiratory disease testing market. National action plans focused on respiratory diseases, surveillance programs, research funding, and public awareness campaigns create an environment conducive to research, innovation, and improved healthcare infrastructure. These initiatives play a vital role in addressing the global burden of respiratory diseases and enhancing patient outcomes.

Key Market Challenges:

High Cost and Lack of Skilled Professionals: Diagnostic procedures come with a substantial cost, and the rapid advancement of technology has led to a shortage of qualified specialists. This shortage hampers the proper execution of procedures, including the handling of instruments and execution of tests, thereby impeding market growth.

Limited Reimbursement Policies: Inadequate or nonexistent reimbursement policies globally can hinder the demand for diagnostic tests, limiting market growth. Without proper reimbursement, patients may hesitate to undergo respiratory disease testing, leading to delayed diagnosis and treatment, particularly in the Asia Pacific region.

Key Market Trends:

Point-of-Care Testing (POCT) Expansion: The expansion of point-of-care testing for respiratory diseases facilitates rapid and convenient testing in various healthcare settings. POCT devices provide quick results, aiding timely diagnosis and monitoring, particularly in resource-limited environments.

Integration of Artificial Intelligence (AI): AI-driven algorithms enhance the accuracy and interpretation of respiratory disease test results, leading to more precise diagnoses and personalized treatment recommendations. AI can identify patterns and correlations that human experts might miss, revolutionizing respiratory disease diagnostics.

Segmental Insights:

Test Type Insights: The market is categorized into Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests. In-vitro Diagnostic Tests are dominant due to their broad adoption and efficacy. Imaging Tests are experiencing rapid growth due to increased demand for precise diagnostic methods and advancements in imaging technology.

End User Insights: Hospitals dominate the market due to their comprehensive care and multidisciplinary approach. Diagnostic centers are growing rapidly, fueled by the increasing trend towards outpatient care and demand for standalone diagnostic services.

Regional Insights: North America maintains dominance due to advanced healthcare infrastructure, healthcare expenditure, and prevalence of respiratory diseases. Asia Pacific is the fastest growing region, driven by a large population base, urbanization, awareness about respiratory diseases, and improving healthcare infrastructure.

Key Market Players

• Beckton Dickinson and Company
• Koninklijke Philips N.V.
• ResMed Inc.
• Medtronic PLC
• Carestream Health
• MG Diagnostic Corporation
• Abbott Laboratories
• ThermoFisher Scientific
• Biomerieux
• QIAGEN

Report Scope:

In this report, the Global Respiratory Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Respiratory Disease Testing Market, By Test Type:

• Imaging Tests
• Mechanical Tests
• In-vitro Diagnostic Tests

Respiratory Disease Testing Market, By Application:

• COPD
• Lung Cancer
• Asthma
• Tuberculosis

Respiratory Disease Testing Market, By End User:

• Hospitals
• Diagnostic Centres
• Others

Respiratory Disease Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Testing Market.

Available Customizations:

• Global Respiratory Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Respiratory Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests)
  • 5.2.2. By Application (COPD, Lung Cancer, Asthma, Tuberculosis)
  • 5.2.3. By End User (Hospitals, Diagnostic Centres, and Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Market Map

6. North America Respiratory Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Respiratory Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Respiratory Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Respiratory Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Application
  • 7.2.3. By End User
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Respiratory Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Respiratory Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Respiratory Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Respiratory Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Respiratory Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Application
  • 8.2.3. By End User
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Respiratory Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Respiratory Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Respiratory Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Respiratory Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Respiratory Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Respiratory Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Application
  • 9.2.3. By End User
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Respiratory Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Respiratory Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Respiratory Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Respiratory Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Application
  • 10.2.3. By End User
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Respiratory Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Respiratory Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Respiratory Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Respiratory Disease Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Services Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. Beckton Dickinson and Company
  • 14.5.2. Koninklijke Philips N.V.
  • 14.5.3. ResMed Inc.
  • 14.5.4. Medtronic PLC
  • 14.5.5. Carestream Health
  • 14.5.6. MG Diagnostic Corporation
  • 14.5.7. Abbott Laboratories
  • 14.5.8. ThermoFisher Scientific
  • 14.5.9. Biomerieux
  • 14.5.10. QIAGEN

15. Strategic Recommendations

16. About Us & Disclaimer